Actively Recruiting
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Led by Hunan Province Tumor Hospital · Updated on 2024-06-04
1200
Participants Needed
1
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
CONDITIONS
Official Title
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand and agree to the clinical trial by signing informed consent
- Age 18 years or older
- Confirmed diagnosis of lung cancer by tissue or cell analysis
- Have failed first-line chemo-immunotherapy treatment
- ECOG performance status score of 0 or 1
- Predicted survival time of at least 12 weeks
- Adequate bone marrow and organ function
- Presence of measurable tumors based on RECIST 1.1 criteria
- Stable brain metastases allowed
You will not qualify if you...
- Received EGFR or VEGFR antibody treatments within 4 weeks before starting study drug
- Radiation therapy within 14 days before study drug start, or ongoing radiation toxicity
- Use of strong CYP1A2 or CYP3A inhibitors or inducers within 1-2 weeks before starting study drug
- Spinal cord compression or meningeal metastasis
- History of other cancers within the past 2 years
- Severe side effects (above grade 1) from prior treatments
- Stroke or brain bleeding within 6 months before study drug start
- Severe or uncontrolled systemic diseases including hypertension and active bleeding
- Active infections including hepatitis B, hepatitis C, HIV, or COVID-19
- Heart diseases or abnormalities
- History of interstitial lung disease or immune-related pneumonia
- Severe nausea, vomiting, swallowing difficulties, or absorption problems
- Live vaccines given within 2 weeks before starting study drug
- Pregnant or breastfeeding women
- Allergy to study drugs or their ingredients
- Other conditions that make participation unsuitable as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yongchang Zhang
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here